A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)
Status:
Completed
Trial end date:
2018-03-24
Target enrollment:
Participant gender:
Summary
This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability,
pharmacokinetics (PK), and pharmacodynamics of a single dose of inclisiran subcutaneous (SC)
injection in participants with mild, moderate, and severe renal impairment compared to
participants with normal renal function.